Left Menu
Development News Edition

China approves drug to cure Alzheimer's; to go on sale from next month


China approves drug to cure Alzheimer's; to go on sale from next month
Image Credit: Pixabay

In a major breakthrough, China has approved a home-grown seaweed-based drug to potentially cure Alzheimer's and it will be available to Chinese patients from next month, state media reported on Monday. China's National Medical Products Administration has approved the market launch of the drug, GV-971, last Saturday, China Daily reported.

The drug can treat mild to moderate forms of the disease and improve cognition, it said. Patients will be able to buy the drug around China from December 29, and more production lines will gradually be put into operation to satisfy the market demand, according to Shanghai Green Valley Pharmaceutical, one of the drug's developers.

The drug is the only Alzheimer's medicine out of more than 320 developed by pharmaceutical companies around the globe to survive clinical trials, despite the investment of hundreds of billions of US dollars over the past two decades, the report said. Extracted from brown algae, the orally taken drug is the world's first multi-targeting and carbohydrate-based drug for Alzheimer's, the administration said.

The first production line for the drug, which will meet the needs of two million patients, will begin running this week. Alzheimer's disease, an irreversible and progressive brain disorder that slowly destroys memory, thinking ability and the capability to carry out simple tasks, affects at least 50 million people worldwide, and the number is expected to increase as populations age.

China has roughly 10 million people with Alzheimer's, the highest in the world. The Chinese Academy of Sciences' Shanghai Institute of Materia Medica, which jointly developed the GV-971 with Green Valley and the Ocean University of China after 22 years of research, said there were previously five medicines with limited efficacy used to treat the disease, which was discovered a century ago.

A phase III clinical trial of the drug involving 818 patients completed in July last year had "proven to continuously and effectively improve cognition among mild to moderate Alzheimer's disease sufferers over a period of nine months," said Geng Meiyu, lead researcher on the drug and a researcher with SIMM. "Addiction and serious toxicity of the therapy haven't been identified in research so far," she said.

Scientists said the drug functions mainly by rebalancing gut microbiota, reducing neuro-inflammation and reducing cognitive impairment. Some doctors from home and abroad, including David Holtzman, chairman of the American Neurological Association, said they believe GV-971 will provide a new medical solution for patients. Preparations are being made for the drug's clinical trials in the US and international multi-centre research, its developers said, with initial communication with the US Food and Drug Administration already completed.

"Green Valley has established a professional team and hired world-renowned experts in this field as consultants in preparation for initiating clinical trials in the US," said Lyu Songtao, the company's chairman. "We don't exclude the possibility of collaborating with international research institutions to perform clinical trials in the US," the Daily report quoted Lyu as saying.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION/BLOG/INTERVIEW

JNU Administration's 100-meter challenge before JNUSU

For the first time in its history, Jawaharlal Nehru University JNU Administration is seeking permanent deployment of local police to keep protesting students at 100 meters away from the Administrative Block. It would be interesting to see h...

Sentiment Analysis of Twitter users during COP25: Governments losing trust on Climate Action

Sentiment analysis of Twitter users during COP25 in Madrid, being held from December 2-13, shows widespread fear on climate change due to global warming but almost no trust on governments in meeting the emission targets. In the analysis the...

These innovators are making humanitarian response more efficient

These alarming trends prompt a call for the world to not only address the ongoing crisis but also to adopt innovative approaches to fulfill the growing humanitarian needs in such emergencies. ...

Hyderabad Encounter: A sentiment analysis of public mood on day of encounter

Sentiment analysis of twitter users revealed that they showered salutes on Hyderabad police for eliminating alleged gang rapists of the veterinary doctor but only a few believe in cops version of successive events leading to encounter....

Videos

Latest News

Brazil Amazon deforestation climbs more than 100% in November over same month last year -gov't agency

Deforestation in Brazils Amazon jumped to the highest level for the month of November since record-keeping began in 2015, according to preliminary government data published on Friday. Destruction of the worlds largest tropical rainforest to...

Pompeo warns Iran of 'decisive response' if harm in Iraq

Secretary of State Mike Pompeo on Friday warned Iran of a decisive response if US interests are harmed in Iraq, after a series of rocket attacks on bases. We must... use this opportunity to remind Irans leaders that any attacks by them, or ...

US Supreme Court to hear Trump tax return case next year

The US Supreme Court agreed Friday to hear cases next year over the release of Donald Trumps tax returns and financial records, setting the stage for a ruling during the presidential election campaign. Trump has been seeking to block access...

'Bridget Jones' actor Colin Firth and wife split after 22 years

British actor Colin Firth and his Italian wife on Friday announced they had split up after 22 years of marriage. Firth, 59, known for playing stiff-upper-lipped Englishmen in films like Love Actually, Bridget Joness Diary and a television v...

Give Feedback